English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Role of a combined soluble interleukine-2 receptor alpha (sIL-R2α) and CA-125 serum marker assay for detection of ovarian cancer Detection of ovarian cancer can be improved using a combined diagnostic test consisting of Ca-125 and serum interleukine-2 receptor alpha (sIL-R2α) at a particular threshold. The objective of the study was to evaluate the accuracy of a diagnostic marker assay that combined Ca-125 and serum interleukine-2 receptor alpha. A case-control study of 38 patients with ovarian cancer, 40 patients with benign ovarian diseases and 31 age-matched healthy controls was designed. Ca-125 and sIL-2Rα were detected in patients' serum by standardized chemiluminescent immunometric assays. For Ca-125, a standard cutoff level of 21 U/ml was applied and for sIL-R2α — two cutoff levels were calculated from women included in the control group — one as a mean concentration and the other as an upper limit of a 95% confidence interval. Mean serum concentrations among ovarian cancer patients for CA125 and sIL-2Rα were 265.9 ± 40.2 U/ml and 651.0 ± 50.5 U/ml, respectively. The upper limit of the 95% confidence interval for a healthy control group of women was 304.5 U/ml for sIL-2Rα. Sensitivity and specificity of 89.4% and 85.9% was achieved when CA125 was combined together with sIL-2Rα at a threshold of 304.5U/ml with the condition that both markers are elevated. Sensitivity and specificity of 92.5% and 88.4% was observed when both biomarkers were applied to menopausal women. Serum sIL-2Rα in combination with CA125 can be used as a differential diagnostic test for ovarian cancer at a specific threshold, especially among menopausal women. Seruma šķīstošā interleikīna 2 receptora alfa (sIL-R2α) un CA-125 kombinētais tests olnīcu vēža diagnostikai Olnīcu vēža diagnostiku var uzlabot, izmantojot kombinēto diagnostikas testu, kas sastāv no olnīcu vēža biomarķiera Ca125 un serumā šķīstošā interleikīna 2 receptora alfa. Pētījuma mērķis bija novērtēt diagnostiskā testa precizitāti olnīcu vēža diagnostikā. Gadījumu kontroles pētījumā bija iesaistītas 38 pacientes ar olnīcu vēzi, 40 pacientes ar labdabīgu olnīcu audzēju un 31 vecumam atbilstošas veselas sievietes kontroles grupā. Ar olnīcu vēzi asociētā antigēna Ca-125 un serumā šķīstošā interleikīna 2 receptora alfa koncentrācija tika noteikta, izmantojot standartizētu hemiluminiscences imunometriskās analīzes metodi. Kā robežvērtība biomarķierim Ca125 tika izmantota seruma koncentrācija 21 U/ml, biomarķierim sIL-R2α tika izmantoti divi robežlielumi — aprēķinātā vidējā seruma koncentrācija un 95% konfidences intervāla augšējā robeža starp kontroles grupas sievietēm. Vidējā seruma koncentrācija olnīcu vēža pacientēm biomarķieriem CA125 un sIL-2Rα bija atbilstoši 265,9 ± 40,2 U/ml un 651,0 ± 50,5 U/ml. Diagnostiskā testa jutīgums un specifiskums sasniedza 89,4% un 85,9%, kad CA125 tika kombinēts kopā ar sIL-2Rα pie robežvērtības 304,5 U/ml ar nosacījumu, ka abām biomarķieru koncentrācijām serumā ir jābūt paaugstinātām. Menopauzē esošu sieviešu populācijā diagnostiskā testa jutīgums un specifiskums sasniedza 92.5% un 88,4%. Serumā šķīstošā interleikīna 2 receptora alfa koncentrācijas noteikšanu serumā kopā ar biomarķieri Ca125 var izmantot kā diagnostisko testu olnīcu vēža diferenciāldiagnostikai pie noteiktiem robežlielumiem, īpaši menopauzē esošu sieviešu populācijā.

proceedings of the latvian academy of sciences. section b, natural sciences/latvijas zinātņu akadēmijas vēstis. a daļa, humanitārās un sociālās zinātnes